The study analyzed the role of cFLIP in breast cancer cells' resistance to TRAIL-induced apoptosis.
Such conclusion was drawn from the evidence that the inhibition of their expression through treatments with Doxorubicin (anthracycline, widely used in chemotherapy) or with SAHA (Histone deacetylases inhibitor), as well as the silencing of its expression through cFLIP siRNA oligos (small interfering RNA), resulted in the sensitisation of breast cancer cells to TRAIL-induced apoptosis.
The researchers have proved that cFLIP plays a survival role in tumorous and non-tumorous breast epithelial cells, since the inhibition of its expression induces apoptosis.
The presentation, titled "Antisense Inhibition of cFLIP Promotes Transplant Acceptance by Sensitizing Responding T Cells to Undergo Activation Induced Apoptosis," was presented by AVI senior scientist Dan Mourich, Ph.
During this process a regulatory protein called cFLIP is produced, blocking apoptosis, or programmed cell death, in the activated lymphocytes.